Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 402

1.

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Micheaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Leukemia. 2020 Feb 4. doi: 10.1038/s41375-020-0725-0. [Epub ahead of print]

PMID:
32020044
2.

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.

Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M M.D, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P.

ESMO Open. 2020 Jan;5(1). pii: e000611. doi: 10.1136/esmoopen-2019-000611.

3.

Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.

Hanekamp D, Bachas C, van de Loosdrecht A, Ossenkoppele G, Cloos J.

Pathology. 2020 Feb;52(2):289-291. doi: 10.1016/j.pathol.2019.09.021. Epub 2019 Dec 26. No abstract available.

PMID:
31883670
4.

Minimal residual disease and stem cell transplantation outcomes.

Cloos J, Ossenkoppele GJ, Dillon R.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):617-625. doi: 10.1182/hematology.2019000006.

PMID:
31808862
5.

TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.

Cucchi DGJ, Bachas C, Klein K, Huttenhuis S, Zwaan CM, Ossenkoppele GJ, Janssen JMWM, Kaspers GL, Cloos J.

Br J Haematol. 2019 Oct 6. doi: 10.1111/bjh.16229. [Epub ahead of print]

PMID:
31588562
6.

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.

Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia E, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M.

Am J Hematol. 2019 Nov;94(11):1236-1243. doi: 10.1002/ajh.25628. Epub 2019 Sep 14.

PMID:
31456269
7.

Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.

de Jong G, Janssen JJWM, Biemond BJ, Zeerleder SS, Ossenkoppele GJ, Visser O, Nur E, Meijer E, Hazenberg MD.

Eur J Haematol. 2019 Nov;103(5):491-499. doi: 10.1111/ejh.13315. Epub 2019 Aug 14.

8.

Can we incorporate MRD assessment into clinical practice in AML?

Ossenkoppele G, Schuurhuis GJ, van de Loosdrecht A, Cloos J.

Best Pract Res Clin Haematol. 2019 Jun;32(2):186-191. doi: 10.1016/j.beha.2019.05.003. Epub 2019 May 10. Review.

PMID:
31204000
9.

Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.

Santini V, Ossenkoppele GJ.

Crit Rev Oncol Hematol. 2019 Aug;140:1-7. doi: 10.1016/j.critrevonc.2019.05.013. Epub 2019 May 25. Review.

PMID:
31153036
10.

Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.

Ossenkoppele G, Montesinos P.

Crit Rev Oncol Hematol. 2019 Jun;138:6-13. doi: 10.1016/j.critrevonc.2019.03.003. Epub 2019 Mar 16. Review.

PMID:
31092386
11.

The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?

van Spronsen MF, Westers TM, Lissenberg-Witte BI, Wondergem M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2019 Dec;104(12):e547-e550. doi: 10.3324/haematol.2018.212563. Epub 2019 Apr 19. No abstract available.

12.

Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.

Moshaver B, Wouters RF, Kelder A, Ossenkoppele GJ, Westra GAH, Kwidama Z, Rutten AR, Kaspers GJL, Zweegman S, Cloos J, Schuurhuis GJ.

Leuk Res. 2019 Jun;81:27-34. doi: 10.1016/j.leukres.2019.04.004. Epub 2019 Apr 9.

PMID:
31002948
13.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, Kooy RVM, de Weerdt O, Breems D, Klein S, Kuball J, Deeren D, Terpstra W, Vekemans MC, Ossenkoppele GJ, Vellenga E, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2019 Mar 28;133(13):1457-1464. doi: 10.1182/blood-2018-10-879866. Epub 2019 Jan 10.

PMID:
30630862
14.

Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.

Reedijk AMJ, Klein K, Coebergh JWW, Kremer LC, Dinmohamed AG, de Haas V, Versluijs AB, Ossenkoppele GJ, Beverloo HB, Pieters R, Zwaan CM, Kaspers GJL, Karim-Kos HE.

Leukemia. 2019 Jun;33(6):1349-1359. doi: 10.1038/s41375-018-0314-7. Epub 2018 Dec 19.

PMID:
30568171
15.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2019 May;33(5):1102-1112. doi: 10.1038/s41375-018-0326-3. Epub 2018 Dec 12.

PMID:
30542144
16.

IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.

Verhagen HJMP, van Gils N, Martiañez T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui ML, de Vos Klootwijk LLE, Menezes RX, Çil M, Roemer MGM, Vermue E, Heukelom S, Zweegman S, Janssen JJWM, Ossenkoppele GJ, Schuurhuis GJ, Smit L.

Cell Rep. 2018 Dec 11;25(11):3021-3035.e5. doi: 10.1016/j.celrep.2018.11.062.

17.

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Freeman SD, Hills RK, Russell NH; UK NCRI AML Trial Group, Cloos J, Kelder A, Ossenkoppele GJ, Schuurhuis GJ; HOVON AML Trial Group.

Br J Haematol. 2019 Jul;186(1):130-133. doi: 10.1111/bjh.15698. Epub 2018 Dec 5. No abstract available.

PMID:
30520018
18.

Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.

Schuurhuis GJ, Ossenkoppele GJ, Kelder A, Cloos J.

Expert Rev Hematol. 2018 Dec;11(12):921-935. doi: 10.1080/17474086.2018.1549479. Review.

PMID:
30466339
19.

Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.

Morsink LM, Walter RB, Ossenkoppele GJ.

Blood Rev. 2019 Mar;34:26-33. doi: 10.1016/j.blre.2018.10.003. Epub 2018 Nov 1. Review.

PMID:
30401586
20.

Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands.

Kalin B, Pijnappel EN, van Gelder M, Visser O, van de Loosdrecht AA, Ossenkoppele GJ, Cornelissen JJ, Dinmohamed AG, Jongen-Lavrencic M.

Cancer Epidemiol. 2018 Dec;57:90-96. doi: 10.1016/j.canep.2018.09.007. Epub 2018 Oct 20.

PMID:
30347337
21.

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ.

Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. No abstract available.

22.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

23.

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH.

Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772.

24.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, Kwidama Z, de Moerloose B, de Bont ESJM, Lissenberg-Witte BI, Zweegman S, Verwer F, Vandepoele K, Schuurhuis GJ, Sonneveld E, Cloos J.

Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.

PMID:
29669779
25.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

26.

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J.

Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.

27.

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.

Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G, Vonk M, Snel AN, Scheick JR, Scholten WJ, Carbaat-Ham J, Veldhuizen D, Hanekamp D, Oussoren-Brockhoff YJM, Kaspers GJL, Schuurhuis GJ, Sasser AK, Ossenkoppele G.

J Vis Exp. 2018 Mar 5;(133). doi: 10.3791/56386.

28.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

29.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.

30.

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.

Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O.

Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87. No abstract available.

31.

Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes.

van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, van de Loosdrecht AA.

Am J Hematol. 2017 Nov;92(11):E631-E634. doi: 10.1002/ajh.24867. Epub 2017 Aug 24. No abstract available.

32.

Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?

Martiáñez Canales T, de Leeuw DC, Vermue E, Ossenkoppele GJ, Smit L.

Cancers (Basel). 2017 Jun 30;9(7). pii: E74. doi: 10.3390/cancers9070074. Review.

33.

The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.

van Solinge TS, Zeijlemaker W, Ossenkoppele GJ, Cloos J, Schuurhuis GJ.

Cytometry B Clin Cytom. 2018 Jan;94(1):151-158. doi: 10.1002/cyto.b.21539. Epub 2017 Aug 15.

34.

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.

Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT.

Haematologica. 2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18.

35.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.

Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7. Review.

PMID:
28386105
36.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

37.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
38.

Response to letter commenting on: Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Witte BI, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2017 Feb;72:269-271. doi: 10.1016/j.ejca.2016.11.029. Epub 2017 Jan 2. No abstract available.

PMID:
28057399
39.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D.

J Clin Oncol. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7.

PMID:
28056193
40.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

PMID:
28049642
41.

MRD in AML: does it already guide therapy decision-making?

Ossenkoppele G, Schuurhuis GJ.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):356-365. Review.

42.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

43.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

PMID:
27733356
44.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

45.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
46.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ.

Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.

PMID:
27416910
47.

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S.

Clin Cancer Res. 2016 Aug 15;22(16):4030-8. doi: 10.1158/1078-0432.CCR-15-2791. Epub 2016 Mar 22.

48.

CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.

Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, Valk P, Ossenkoppele G, Zeijlemaker W, Kaspers G, Cloos J, Schuurhuis GJ.

Br J Haematol. 2016 Apr;173(2):219-35. doi: 10.1111/bjh.13941. Epub 2016 Jan 27.

PMID:
26814163
49.

Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2016 Mar;56:10-20. doi: 10.1016/j.ejca.2015.12.004. Epub 2016 Jan 19.

PMID:
26798967
50.

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.

Ossenkoppele GJ, Janssen JJ, van de Loosdrecht AA.

Haematologica. 2016 Jan;101(1):20-5. doi: 10.3324/haematol.2015.139105. Review.

Supplemental Content

Loading ...
Support Center